Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial

David Wayne Johnson, Carmel Mary Hawley, Brenda Rosser, Elaine Beller, Charles Thompson, Robert G. Fassett, Paolo Ferrari, Stephen McDonald, Eugenie Pedagogos, Alan Cass

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. Methods/design. Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement. Discussion. This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease. Trial Registration. Australian New Zealand Clinical Trials Registry Number ACTRN12608000199314.

LanguageEnglish
Article number8
JournalBMC Nephrology
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Sep 2008
Externally publishedYes

ASJC Scopus subject areas

  • Nephrology

Cite this

Johnson, D. W., Hawley, C. M., Rosser, B., Beller, E., Thompson, C., Fassett, R. G., ... Cass, A. (2008). Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial. BMC Nephrology, 9(1), [8]. https://doi.org/10.1186/1471-2369-9-8
Johnson, David Wayne ; Hawley, Carmel Mary ; Rosser, Brenda ; Beller, Elaine ; Thompson, Charles ; Fassett, Robert G. ; Ferrari, Paolo ; McDonald, Stephen ; Pedagogos, Eugenie ; Cass, Alan. / Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia : A randomized controlled trial. In: BMC Nephrology. 2008 ; Vol. 9, No. 1.
@article{b7fed5e1ddd2489bb94c6697ce9a162b,
title = "Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial",
abstract = "Background. The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. Methods/design. Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement. Discussion. This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease. Trial Registration. Australian New Zealand Clinical Trials Registry Number ACTRN12608000199314.",
author = "Johnson, {David Wayne} and Hawley, {Carmel Mary} and Brenda Rosser and Elaine Beller and Charles Thompson and Fassett, {Robert G.} and Paolo Ferrari and Stephen McDonald and Eugenie Pedagogos and Alan Cass",
year = "2008",
month = "9",
day = "1",
doi = "10.1186/1471-2369-9-8",
language = "English",
volume = "9",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

Johnson, DW, Hawley, CM, Rosser, B, Beller, E, Thompson, C, Fassett, RG, Ferrari, P, McDonald, S, Pedagogos, E & Cass, A 2008, 'Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial', BMC Nephrology, vol. 9, no. 1, 8. https://doi.org/10.1186/1471-2369-9-8

Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia : A randomized controlled trial. / Johnson, David Wayne; Hawley, Carmel Mary; Rosser, Brenda; Beller, Elaine; Thompson, Charles; Fassett, Robert G.; Ferrari, Paolo; McDonald, Stephen; Pedagogos, Eugenie; Cass, Alan.

In: BMC Nephrology, Vol. 9, No. 1, 8, 01.09.2008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia

T2 - BMC Nephrology

AU - Johnson, David Wayne

AU - Hawley, Carmel Mary

AU - Rosser, Brenda

AU - Beller, Elaine

AU - Thompson, Charles

AU - Fassett, Robert G.

AU - Ferrari, Paolo

AU - McDonald, Stephen

AU - Pedagogos, Eugenie

AU - Cass, Alan

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Background. The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. Methods/design. Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement. Discussion. This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease. Trial Registration. Australian New Zealand Clinical Trials Registry Number ACTRN12608000199314.

AB - Background. The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. Methods/design. Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement. Discussion. This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease. Trial Registration. Australian New Zealand Clinical Trials Registry Number ACTRN12608000199314.

UR - http://www.scopus.com/inward/record.url?scp=50249092167&partnerID=8YFLogxK

U2 - 10.1186/1471-2369-9-8

DO - 10.1186/1471-2369-9-8

M3 - Article

VL - 9

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 8

ER -